Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Safety of Rifampicin at High Dose for Difficult-to-Treat Tuberculosis, Protocol for RIAlta Phase 2b/c Trial

  • Espinosa-Pereiro, Juan|||0000-0002-7238-8337
  • Ghimire, Samiksha|||0000-0002-6028-1460
  • Sturkenboom, Marieke G. G.|||0000-0002-3420-0591
  • Alffenaar, Jan-Willem C.|||0000-0001-6703-0288
  • Tavares, Margarida|||0000-0003-4518-2197
  • Aguirre, Sarita|||0000-0002-8752-2762
  • Battaglia, Arturo
  • Molinas, Gladys
  • Tórtola Fernández, María Teresa|||0000-0002-9188-298X
  • Akkerman, Onno|||0000-0001-5638-9260
  • Sánchez Montalvá, Adrián|||0000-0002-2194-5447
  • Magis-Escurra, Cecile|||0000-0001-8424-9425
Previous clinical trials for drug-susceptible tuberculosis (DS-TB) have shown that first-line treatment with doses of rifampicin up to 40 mg/kg are safe and increase the early treatment response for young adults with pulmonary tuberculosis. This may lead to a shorter treatment duration for those persons with TB and a good baseline prognosis, or increased treatment success for vulnerable subgroups (age.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Efficacy of Tocilizumab for hospitalized patients with COVID-19 pneumonia and high IL-6 levels: A randomized controlled trial

  • Sellarès-Nadal, Júlia|||0000-0002-0209-6494
  • Espinosa-Pereiro, Juan|||0000-0002-7238-8337
  • Burgos, Joaquín|||0000-0001-8445-3047
  • Falcó, Vicenç|||0000-0001-9626-0023
  • Guillén-Del-Castillo, Alfredo|||0000-0003-0626-507X
  • Augustin Recio, Salvador|||0000-0002-3515-9033
  • Bañares-Sánchez, Joan
  • Prio-Ruatg, Alba
  • Martínez-Valle, Ferran
  • Kirkegaard, Cristina|||0000-0001-9035-1450
  • Sánchez Montalvá, Adrián|||0000-0002-2194-5447
Background: The objective of this clinical trial is to evaluate the efficacy and safety of IL-6 driven personalized treatment strategy with tocilizumab in patients with severe COVID-19 pneumonia. Trial design: Randomized, controlled, open-label, single-center trial of a tocilizumab treatment strategy in adult patients hospitalized with severe COVID-19 pneumonia and IL-6 serum levels.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Tuberculosis incidence in solid organ transplant recipients in Europe: A multicenter TBnet cohort study

  • Lange, Berit
  • Brehm, Thomas Theo
  • Arend, Sandra M.
  • Arias-Guillén, Miguel
  • Bakker, Marleen
  • Berastegui Garcia, Cristina
  • Los-Arcos, Ibai
  • SÁNCHEZ-MONTALVÁ, ADRIÁN
Progression to tuberculosis; Transplantation; Tuberculosis, Progressió a tuberculosi; Trasplantament; Tuberculosi, Progresión a tuberculosis; Trasplante; Tuberculosis, Background Solid organ transplant (SOT) recipients face elevated tuberculosis risk, yet optimal prevention strategies in low- to medium-incidence regions remain unclear. Methods We conducted a multicenter retrospective cohort study of adult SOT recipients transplanted between 2007 and 2012 at 15 European centers, with follow-up through 2018. The primary outcome was microbiologically confirmed post-transplant tuberculosis. Incidence rates were calculated per 100,000 person-years; standardized incidence ratios (SIRs) used World Health Organization country-specific background rates. Cox models assessed risk factors. Results Among 5805 patients (median age 51; 62.7% male; 73.9% renal transplants), 33.8% were tested for tuberculosis infection and 10.3% received tuberculosis preventive therapy (TPT). Over 33,785 person-years, 23 patients (0.4%) developed tuberculosis (68.0/100,000 person-years). Highest incidence occurred in patients with positive screening but no TPT (233.8/100,000). Incidence was higher in Southern vs. Central Europe (251.9 vs. 28.7/100,000), with pooled SIRs of 12.8 and 3.1, respectively. Tuberculosis risk was elevated among Southern European recipients (HR 22.9) and those with migration history (HR 2.7). Conclusion Tuberculosis risk is increased in European SOT recipients. Regionally adapted prevention strategies, including targeted screening in low-incidence areas and universal screening in higher-incidence regions, are warranted., The authors thank the following persons for their support during the study: Marija Milinkovic, MD, and Milica Kravljaca, MD; Department of Nephrology, University Clinical Center of Serbia, Belgrade, Serbia; This study was investigator-initiated without funding. Raquel Duarte is supported by Portuguese Funds through FCT-Foundation for Science and Technology, I.P., under the projects UIDB/04750/2020 (DOI identifier: https://doi.org/10.54499/UIDB/04750/2020) and LA/P/0064/2020 (DOI identifier: https://doi.org/10.54499/LA/P/0064/2020). Tomas Reischig is supported by the Charles University Cooperatio Program, research areas “Immunity and Infections” and “Internal Disciplines”. Adrián Sánchez-Montalvá was supported by a postdoctoral grant, “Juan Rodes” (JR18/00022), from Instituto de Salud Carlos III through the Ministry of Economy and Competitiveness, Spain during the conception and implementation of the project. Christoph Lange is supported by the German Center for Infection Research (DZIF) under Grant agreement TTU-TB 02.709 for clinical tuberculosis research.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Magnetic Bead Handling Using a Paper-Based Device for Quantitative Point-of-Care Testing

  • Arias Alpizar, Kevin Ricardo
  • Sánchez Cano, Ana
  • Prat Trunas, Judit
  • Sulleiro Igual, Elena
  • Bosch Nicolau, Pau
  • Oliveira Souto, Ines Mercedes
  • Baldrich Rubio, Eva
  • Molina Romero, Israel
  • Salvador Velez, Fernando M
  • Sánchez Montalvá, Adrián
Low-cost assay automation; Malaria quantitative diagnosis; Smartphone colorimetric detection, Automatització d'assaigs de baix cost; Diagnòstic quantitatiu de la malària; Detecció colorimètrica del telèfon intel·ligent, Automatización de ensayos de bajo costo; Diagnóstico cuantitativo de la malaria; Detección colorimétrica de teléfono inteligente, Microfluidic paper-based analytical devices (μPADs) have been extensively proposed as ideal tools for point-of-care (POC) testing with minimal user training and technical requirements. However, most μPADs use dried bioreagents, which complicate production, reduce device reproducibility and stability, and require transport and storage under temperature and humidity-controlled conditions. In this work, we propose a μPAD produced using an affordable craft-cutter and stored at room temperature, which is used to partially automate a single-step colorimetric magneto-immunoassay. As a proof-of-concept, the μPAD has been applied to the quantitative detection of Plasmodium falciparum lactate dehydrogenase (Pf-LDH), a biomarker of malaria infection. In this system, detection is based on a single-step magneto-immunoassay that consists of a single 5-min incubation of the lysed blood sample with immuno-modified magnetic beads (MB), detection antibody, and an enzymatic signal amplifier (Poly-HRP). This mixture is then transferred to a single-piece paper device where, after on-chip MB magnetic concentration and washing, signal generation is achieved by adding a chromogenic enzyme substrate. The colorimetric readout is achieved by the naked eye or using a smartphone camera and free software for image analysis. This μPAD afforded quantitative Pf-LDH detection in <15 min, with a detection limit of 6.25 ng mL−1 when the result was interpreted by the naked eye and 1.4 ng mL−1 when analysed using the smartphone imaging system. Moreover, the study of a battery of clinical samples revealed concentrations of Pf-LDH that correlated with those provided by the reference ELISA and with better sensitivity than a commercial rapid diagnostic test (RDT). These results demonstrate that magneto-immunoassays can be partly automated by employing a μPAD, achieving a level of handling that approaches the requirements of POC testing., This research was funded by Fondo de Investigaciones Sanitarias of Instituto de Salud Carlos III (co-funded by the European Regional Development Fund; grants CPII18/00025, IFI18/00020, JR18/00022 and QUPID EuroNanoMed AC21_2/00021) and La Caixa Foundation (ID 100010434, fellowship LCF/BQ/DI18/11660061). Diagnostic Nanotools is a consolidated group supported by Secretaria d’Universitats i Recerca, Generalitat de Catalunya (2017 SGR 240).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Study of CD27, CD38, HLA-DR and Ki-67 immune profiles for the characterization of active tuberculosis, latent infection and end of treatment

  • Díaz-Fernández, Sergio
  • Villar-Hernández, Raquel
  • Stojanovic, Zoran
  • Fernández, Marco
  • De Souza Galvao, Maria Luiza
  • Tolosa, Guillermo
  • Jiménez Fuentes, Maria Angeles
  • Sánchez Montalvá, Adrián
Mycobacterium tuberculosis; T-cells; Immune response, Tuberculosis micobacteriana; Células T; Respuesta inmune, Tuberculosi micobacteriana; Cèl·lules T; Resposta immune, Background: Current blood-based diagnostic tools for TB are insufficient to properly characterize the distinct stages of TB, from the latent infection (LTBI) to its active form (aTB); nor can they assess treatment efficacy. Several immune cell biomarkers have been proposed as potential candidates for the development of improved diagnostic tools. Objective: To compare the capacity of CD27, HLA-DR, CD38 and Ki-67 markers to characterize LTBI, active TB and patients who ended treatment and resolved TB. Methods: Blood was collected from 45 patients defined according to clinical and microbiological criteria as: LTBI, aTB with less than 1 month of treatment and aTB after completing treatment. Peripheral blood mononuclear cells were stimulated with ESAT-6/CFP-10 or PPD antigens and acquired for flow cytometry after labelling with conjugated antibodies against CD3, CD4, CD8, CD27, IFN-γ, TNF-α, CD38, HLA-DR, and Ki-67. Conventional and multiparametric analyses were done with FlowJo and OMIQ, respectively. Results: The expression of CD27, CD38, HLA-DR and Ki-67 markers was analyzed in CD4+ T-cells producing IFN-γ and/or TNF-α cytokines after ESAT-6/CFP-10 or PPD stimulation. Within antigen-responsive CD4+ T-cells, CD27− and CD38+ (ESAT-6/CFP-10-specific), and HLA-DR+ and Ki-67+ (PPD- and ESAT-6/CFP-10-specific) populations were significantly increased in aTB compared to LTBI. Ki-67 demonstrated the best discriminative performance as evaluated by ROC analyses (AUC > 0.9 after PPD stimulation). Data also points to a significant change in the expression of CD38 (ESAT-6/CFP-10-specific) and Ki-67 (PPD- and ESAT-6/CFP-10-specific) after ending the anti-TB treatment regimen. Furthermore, ratio based on the CD27 median fluorescence intensity in CD4+ T-cells over Mtb-specific CD4+ T-cells showed a positive association with aTB over LTBI (ESAT-6/CFP-10-specific). Additionally, multiparametric FlowSOM analyses revealed an increase in CD27 cell clusters and a decrease in HLA-DR cell clusters within Mtb-specific populations after the end of treatment. Conclusion: Our study independently confirms that CD27−, CD38+, HLA-DR+ and Ki-67+ populations on Mtb-specific CD4+ T-cells are increased during active TB disease. Multiparametric analyses unbiasedly identify clusters based on CD27 or HLA-DR whose abundance can be related to treatment efficacy. Further studies are necessary to pinpoint the convergence between conventional and multiparametric approaches., This research was supported by a grant from the Instituto de Salud Carlos III (PI18/00411, PI19/01408 and CP20/00070), integrated in the Plan Nacional de I + D + I and cofunded by the ISCIII Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER); a grant from the Sociedad Española de Neumología y Cirugía Torácica (project 25/2016; SEPAR; Barcelona, Spain); and from the European Union’s Horizon 2020 Research and Innovation Programme under the Marie Skłodowska-Curie grant agreement no. 823854 (INNOVA4TB). JD and IL are researchers from the Miguel Servet programme. AS-M is supported by a Juan Rodés (JR18/00022) postdoctoral fellowship from ISCIII.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Study of CD27, CD38, HLA-DR and Ki-67 immune profiles for the characterization of active tuberculosis, latent infection and end of treatment

  • Díaz-Fernández, Sergio
  • Villar-Hernández, Raquel
  • Stojanovic, Zoran
  • Fernández, Marco
  • De Souza Galvao, Maria Luiza
  • Tolosa, Guillermo
  • Jiménez Fuentes, Maria Angeles
  • Sánchez Montalvá, Adrián
Mycobacterium tuberculosis; T-cells; Immune response, Tuberculosis micobacteriana; Células T; Respuesta inmune, Tuberculosi micobacteriana; Cèl·lules T; Resposta immune, Background: Current blood-based diagnostic tools for TB are insufficient to properly characterize the distinct stages of TB, from the latent infection (LTBI) to its active form (aTB); nor can they assess treatment efficacy. Several immune cell biomarkers have been proposed as potential candidates for the development of improved diagnostic tools. Objective: To compare the capacity of CD27, HLA-DR, CD38 and Ki-67 markers to characterize LTBI, active TB and patients who ended treatment and resolved TB. Methods: Blood was collected from 45 patients defined according to clinical and microbiological criteria as: LTBI, aTB with less than 1 month of treatment and aTB after completing treatment. Peripheral blood mononuclear cells were stimulated with ESAT-6/CFP-10 or PPD antigens and acquired for flow cytometry after labelling with conjugated antibodies against CD3, CD4, CD8, CD27, IFN-γ, TNF-α, CD38, HLA-DR, and Ki-67. Conventional and multiparametric analyses were done with FlowJo and OMIQ, respectively. Results: The expression of CD27, CD38, HLA-DR and Ki-67 markers was analyzed in CD4+ T-cells producing IFN-γ and/or TNF-α cytokines after ESAT-6/CFP-10 or PPD stimulation. Within antigen-responsive CD4+ T-cells, CD27− and CD38+ (ESAT-6/CFP-10-specific), and HLA-DR+ and Ki-67+ (PPD- and ESAT-6/CFP-10-specific) populations were significantly increased in aTB compared to LTBI. Ki-67 demonstrated the best discriminative performance as evaluated by ROC analyses (AUC > 0.9 after PPD stimulation). Data also points to a significant change in the expression of CD38 (ESAT-6/CFP-10-specific) and Ki-67 (PPD- and ESAT-6/CFP-10-specific) after ending the anti-TB treatment regimen. Furthermore, ratio based on the CD27 median fluorescence intensity in CD4+ T-cells over Mtb-specific CD4+ T-cells showed a positive association with aTB over LTBI (ESAT-6/CFP-10-specific). Additionally, multiparametric FlowSOM analyses revealed an increase in CD27 cell clusters and a decrease in HLA-DR cell clusters within Mtb-specific populations after the end of treatment. Conclusion: Our study independently confirms that CD27−, CD38+, HLA-DR+ and Ki-67+ populations on Mtb-specific CD4+ T-cells are increased during active TB disease. Multiparametric analyses unbiasedly identify clusters based on CD27 or HLA-DR whose abundance can be related to treatment efficacy. Further studies are necessary to pinpoint the convergence between conventional and multiparametric approaches., This research was supported by a grant from the Instituto de Salud Carlos III (PI18/00411, PI19/01408 and CP20/00070), integrated in the Plan Nacional de I + D + I and cofunded by the ISCIII Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER); a grant from the Sociedad Española de Neumología y Cirugía Torácica (project 25/2016; SEPAR; Barcelona, Spain); and from the European Union’s Horizon 2020 Research and Innovation Programme under the Marie Skłodowska-Curie grant agreement no. 823854 (INNOVA4TB). JD and IL are researchers from the Miguel Servet programme. AS-M is supported by a Juan Rodés (JR18/00022) postdoctoral fellowship from ISCIII.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Tuberculosis incidence in solid organ transplant recipients in Europe: A multicenter TBnet cohort study

  • Lange, Berit
  • Brehm, Thomas Theo
  • Arend, Sandra M.
  • Arias-Guillén, Miguel
  • Bakker, Marleen
  • Berastegui Garcia, Cristina
  • Los-Arcos, Ibai
  • SÁNCHEZ-MONTALVÁ, ADRIÁN
Progression to tuberculosis; Transplantation; Tuberculosis, Progressió a tuberculosi; Trasplantament; Tuberculosi, Progresión a tuberculosis; Trasplante; Tuberculosis, Background Solid organ transplant (SOT) recipients face elevated tuberculosis risk, yet optimal prevention strategies in low- to medium-incidence regions remain unclear. Methods We conducted a multicenter retrospective cohort study of adult SOT recipients transplanted between 2007 and 2012 at 15 European centers, with follow-up through 2018. The primary outcome was microbiologically confirmed post-transplant tuberculosis. Incidence rates were calculated per 100,000 person-years; standardized incidence ratios (SIRs) used World Health Organization country-specific background rates. Cox models assessed risk factors. Results Among 5805 patients (median age 51; 62.7% male; 73.9% renal transplants), 33.8% were tested for tuberculosis infection and 10.3% received tuberculosis preventive therapy (TPT). Over 33,785 person-years, 23 patients (0.4%) developed tuberculosis (68.0/100,000 person-years). Highest incidence occurred in patients with positive screening but no TPT (233.8/100,000). Incidence was higher in Southern vs. Central Europe (251.9 vs. 28.7/100,000), with pooled SIRs of 12.8 and 3.1, respectively. Tuberculosis risk was elevated among Southern European recipients (HR 22.9) and those with migration history (HR 2.7). Conclusion Tuberculosis risk is increased in European SOT recipients. Regionally adapted prevention strategies, including targeted screening in low-incidence areas and universal screening in higher-incidence regions, are warranted., The authors thank the following persons for their support during the study: Marija Milinkovic, MD, and Milica Kravljaca, MD; Department of Nephrology, University Clinical Center of Serbia, Belgrade, Serbia; This study was investigator-initiated without funding. Raquel Duarte is supported by Portuguese Funds through FCT-Foundation for Science and Technology, I.P., under the projects UIDB/04750/2020 (DOI identifier: https://doi.org/10.54499/UIDB/04750/2020) and LA/P/0064/2020 (DOI identifier: https://doi.org/10.54499/LA/P/0064/2020). Tomas Reischig is supported by the Charles University Cooperatio Program, research areas “Immunity and Infections” and “Internal Disciplines”. Adrián Sánchez-Montalvá was supported by a postdoctoral grant, “Juan Rodes” (JR18/00022), from Instituto de Salud Carlos III through the Ministry of Economy and Competitiveness, Spain during the conception and implementation of the project. Christoph Lange is supported by the German Center for Infection Research (DZIF) under Grant agreement TTU-TB 02.709 for clinical tuberculosis research.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Magnetic Bead Handling Using a Paper-Based Device for Quantitative Point-of-Care Testing

  • Arias Alpizar, Kevin Ricardo
  • Sánchez Cano, Ana
  • Prat Trunas, Judit
  • Sulleiro Igual, Elena
  • Bosch Nicolau, Pau
  • Oliveira Souto, Ines Mercedes
  • Baldrich Rubio, Eva
  • Molina Romero, Israel
  • Salvador Velez, Fernando M
  • Sánchez Montalvá, Adrián
Low-cost assay automation; Malaria quantitative diagnosis; Smartphone colorimetric detection, Automatització d'assaigs de baix cost; Diagnòstic quantitatiu de la malària; Detecció colorimètrica del telèfon intel·ligent, Automatización de ensayos de bajo costo; Diagnóstico cuantitativo de la malaria; Detección colorimétrica de teléfono inteligente, Microfluidic paper-based analytical devices (μPADs) have been extensively proposed as ideal tools for point-of-care (POC) testing with minimal user training and technical requirements. However, most μPADs use dried bioreagents, which complicate production, reduce device reproducibility and stability, and require transport and storage under temperature and humidity-controlled conditions. In this work, we propose a μPAD produced using an affordable craft-cutter and stored at room temperature, which is used to partially automate a single-step colorimetric magneto-immunoassay. As a proof-of-concept, the μPAD has been applied to the quantitative detection of Plasmodium falciparum lactate dehydrogenase (Pf-LDH), a biomarker of malaria infection. In this system, detection is based on a single-step magneto-immunoassay that consists of a single 5-min incubation of the lysed blood sample with immuno-modified magnetic beads (MB), detection antibody, and an enzymatic signal amplifier (Poly-HRP). This mixture is then transferred to a single-piece paper device where, after on-chip MB magnetic concentration and washing, signal generation is achieved by adding a chromogenic enzyme substrate. The colorimetric readout is achieved by the naked eye or using a smartphone camera and free software for image analysis. This μPAD afforded quantitative Pf-LDH detection in <15 min, with a detection limit of 6.25 ng mL−1 when the result was interpreted by the naked eye and 1.4 ng mL−1 when analysed using the smartphone imaging system. Moreover, the study of a battery of clinical samples revealed concentrations of Pf-LDH that correlated with those provided by the reference ELISA and with better sensitivity than a commercial rapid diagnostic test (RDT). These results demonstrate that magneto-immunoassays can be partly automated by employing a μPAD, achieving a level of handling that approaches the requirements of POC testing., This research was funded by Fondo de Investigaciones Sanitarias of Instituto de Salud Carlos III (co-funded by the European Regional Development Fund; grants CPII18/00025, IFI18/00020, JR18/00022 and QUPID EuroNanoMed AC21_2/00021) and La Caixa Foundation (ID 100010434, fellowship LCF/BQ/DI18/11660061). Diagnostic Nanotools is a consolidated group supported by Secretaria d’Universitats i Recerca, Generalitat de Catalunya (2017 SGR 240).